Navigation Links
Romark Announces Clinical Trial Results for New Influenza Drug Presented at IDSA Meeting 2011
Date:10/21/2011

se group and 116.7 hours for patients receiving the placebo. Time to resolution of symptoms for the low dose group were less than for the placebo, but the difference was not statistically significant (P=0.521). Patients in the 600 mg NTZ treatment group also experienced statistically significant reductions in quantitative viral shedding compared to patients receiving the placebo (P=0.0006). Adverse events were similar for the three treatment groups except for a higher rate of mild diarrhea in the 600 mg treatment group (8.1%) compared to the placebo treatment group (3.3%).

About the Phase 2 Clinical Trials

Two Phase 2 clinical trials, one in pediatric patients age 1 to 11 years, and another in adults and adolescents age 12 – 65 years, were conducted at a single center in Cajamarca, Peru.  Patients were enrolled based upon symptoms consistent with influenza (fever, at least one respiratory symptom and one constitutional symptom) and randomly assigned to receive treatment with NTZ or placebo in double-blind fashion.  Patients in the pediatric study received 100 mg NTZ (age 12 – 47 months), 200 mg NTZ (age 4 – 11 years) or placebo twice daily for five days as an oral suspension.  Patients enrolled in the study of adults and adolescents received 500 mg NTZ or placebo twice daily for five days as an oral tablet.  Identification of respiratory viruses at baseline was performed by ELISA.  Patients were visited daily by a study nurse to monitor the health of the patients, ensure compliance with the study medication and recording of symptoms in a patient diary, and to collect tissue with nasal secretions, and patients were followed up at study day 7.  The primary efficacy endpoint was time from first dose to alleviation of symptoms (all symptoms absent or mild and remained so for 24 hours).  

One-hundred children, median age 3 years, were enrolled in the pediatric trial (50 per tre
'/>"/>

SOURCE Romark Laboratories, L.C.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Romark Laboratories Raises $18 Million in Institutional Financing
3. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
4. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
5. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
6. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
7. NeuroFocus and New Scientist Magazine Apply Neuromarketing to Select Cover Design
8. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
9. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
10. Romark Announces Data Presented at AASLD Meeting 2010
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014 The Parenteral Drug Association ... global post-approval changes protocols. The new ... topic expressed by industry participants and regulatory authority representatives ... month in Washington, DC . Representatives ... hand for the workshop. Attendees indicated openness to engaging ...
(Date:9/19/2014)... DALLAS , Sept. 19, 2014 ... Market Outlook to 2020″, provides key ... General Surgery devices market. The report ... dollars, and volume (in units) within ... Cystoscopes, Colonoscopes, Sigmoidoscopes, Esophagoscopes & Gastroscopes, ...
(Date:9/19/2014)... 19, 2014  The board of directors of AbbVie ... cash dividend of $0.42 per share.  ... stockholders of record at the close of business on ... a global, research-based biopharmaceutical company formed in 2013 following ... its expertise, dedicated people and unique approach to innovation ...
Breaking Medicine Technology:PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5
... , the leader in heart rate monitoring and fitness assessment ... Rate Technology Supplier" for U.S. Soccer through 2013.  ... major national and international events, including the London 2012 Olympic ... be used to help these nine National Teams gain a ...
... Feb. 29, 2012  Four Rivers Software Systems, Inc. the ... to the healthcare industry, is pleased to announce ... part of this critical release, we have included ... that will benefit users.  The ...
Cached Medicine Technology:Polar Named Official Heart Rate Technology Supplier of U.S. Soccer Federation 2Polar Named Official Heart Rate Technology Supplier of U.S. Soccer Federation 3Four Rivers Software Systems Launches TMS 2012.5.5 2
(Date:9/19/2014)... “Copay coupons,” a drug manufacturer marketing tactic ... patients with prescription drug coverage, may now be infiltrating ... from the Department of Health and Human Services ... prohibit suppliers from offering side-payments to increase sales of ... The report highlights that two recent surveys, including one ...
(Date:9/19/2014)... New York, NY (PRWEB) September 19, 2014 ... by PR News at the Platinum PR and Top ... Grand Hyatt in New York City. Camino received honorable ... a Shoestring Campaign” — for its work elevating Latina ... with this incredible organization and be a part of ...
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 According ... manufacturers of the embattled blood-thinner Xarelto, named as defendants ... of Common Pleas, have moved the court to dismiss ... do not have sufficient connection with Philadelphia.* The cases ... et al. (No. 140304328; Pa. Comm. Pls., Philadelphia Cty.), ...
(Date:9/19/2014)... -- Although there is mounting evidence that muscle-strength ... older adults in the United States don,t engage ... research. Less than one-quarter of adults over ... Department of Health and Human Services, the study ... health and fitness and staying independent, researchers advised. ...
(Date:9/19/2014)... MetroMD, a leading anti-ageing clinic has called its HGH ... therapy has grown tremendously across USA in the last decade ... dependable. It has far reaching benefits for ageing men and ... healthy and active lifestyle even beyond their middle age. ... at MetroMD said, “HGH or Human Growth hormones are the ...
Breaking Medicine News(10 mins):Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2
... Company Locations in Alabama, Georgia, Indiana, Iowa, Kansas, ... Texas, Virginia and WisconsinWASHINGTON, Jan. 15 SouthernCare ... the United States a total of $24.7 million ... submitted false claims to the government for patients ...
... coalition of clergy and lay members from faith organizations throughout ... Senator Richard Burr to end his opposition to legislation that ... over tobacco products. The legislation would protect kids from ... to filibuster the legislation if it was brought to the ...
... required for foods from these animals, agency says , , ... and Drug Administration on Thursday issued its final regulations ... rules do not require consumer labeling for foods from ... (rDNA) to introduce new characteristics or traits into an ...
... 15 Boston Scientific Corporation (NYSE: BSX ) today ... Circuit. The case involves a Boston Scientific patent, which in ... the decision, the Court found that the patent was invalid as ... by Johnson and Johnson of a 2005 jury verdict in the ...
... of Trade Alerts on stocks making news today. Investors can ... visiting: http://www.BeaconEquity.com/m Today,s Trade Alerts include: Eli Lily ... (NYSE: PCS ), ConAgra Foods Inc. (NYSE: ... ), Target Corp. (NYSE: TGT ) and Dow ...
... around 50 percent, despite proven benefits, report says , , THURSDAY, ... colon cancer saves lives, but too few Americans are getting ... report shows. , The rate of screening for breast and ... the rate of colorectal cancer screening has increased but not ...
Cached Medicine News:Health News:Alabama-Based Hospice Company Pays U.S. $24.7 Million to Settle Health Care Fraud Claims 2Health News:North Carolina Faith Leaders Call on Sen. Burr to End Filibuster Threat of Legislation to Protect Kids From Tobacco 2Health News:North Carolina Faith Leaders Call on Sen. Burr to End Filibuster Threat of Legislation to Protect Kids From Tobacco 3Health News:FDA Issues Final Regulations for Genetically Engineered Animals 2Health News:FDA Issues Final Regulations for Genetically Engineered Animals 3Health News:Boston Scientific Announces Court Decision 2Health News:Boston Scientific Announces Court Decision 3Health News:Beacon Equity Issues Technical Trade Alerts on Headline Stocks: LLY, PCS, CAG, FRX, TGT, DOW 2Health News:More Americans Urged to Get Cancer Screenings 2Health News:More Americans Urged to Get Cancer Screenings 3
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... are available in two versions. ... a clotting activator and is ... serum is required for testing ... is suitable where the testing ...
Medicine Products: